Qualigen Therapeutics (QLGN) Competitors $3.87 +0.01 (+0.26%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends QLGN vs. CHRO, THAR, ARTL, GENE, CPHI, GRTS, OGEN, NBY, NCNA, and TCRTShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Chromocell Therapeutics (CHRO), Tharimmune (THAR), Artelo Biosciences (ARTL), Genetic Technologies (GENE), China Pharma (CPHI), Gritstone bio (GRTS), Oragenics (OGEN), NovaBay Pharmaceuticals (NBY), NuCana (NCNA), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Chromocell Therapeutics Tharimmune Artelo Biosciences Genetic Technologies China Pharma Gritstone bio Oragenics NovaBay Pharmaceuticals NuCana Alaunos Therapeutics Chromocell Therapeutics (NYSE:CHRO) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of CHRO or QLGN? 78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in CHRO or QLGN? Qualigen Therapeutics received 6 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Chromocell Therapeutics an outperform vote while only 87.50% of users gave Qualigen Therapeutics an outperform vote. CompanyUnderperformOutperformChromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesQualigen TherapeuticsOutperform Votes787.50% Underperform Votes112.50% Does the media prefer CHRO or QLGN? In the previous week, Qualigen Therapeutics had 2 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 3 mentions for Qualigen Therapeutics and 1 mentions for Chromocell Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.50 beat Chromocell Therapeutics' score of 0.00 indicating that Qualigen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chromocell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CHRO or QLGN more profitable? Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% Qualigen Therapeutics N/A N/A -424.18% Which has stronger valuation & earnings, CHRO or QLGN? Chromocell Therapeutics has higher earnings, but lower revenue than Qualigen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38MN/AN/AQualigen Therapeutics$4.98M0.19-$13.42MN/AN/A Do analysts prefer CHRO or QLGN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryChromocell Therapeutics beats Qualigen Therapeutics on 6 of the 11 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$952,000.00$6.43B$5.04B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E RatioN/A10.10122.4217.58Price / Sales0.19243.351,179.2973.96Price / CashN/A22.1633.5632.51Price / Book-0.195.474.694.68Net Income-$13.42M$153.61M$118.98M$225.87M7 Day Performance-6.07%-4.33%-2.45%-2.03%1 Month Performance-53.71%-8.62%-4.03%0.07%1 Year Performance-89.10%28.78%29.80%24.55% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$3.87+0.3%N/A-89.1%$950,000.00$4.98M0.0050News CoverageCHROChromocell TherapeuticsN/A$0.62+14.8%N/AN/A$3.73MN/A0.004News CoverageTHARTharimmune0.8279 of 5 stars$2.50+2.9%N/A-96.1%$3.73MN/A0.002ARTLArtelo Biosciences3.2126 of 5 stars$1.15+3.6%$5.00+334.8%-8.7%$3.71MN/A-0.405Analyst RevisionGENEGenetic Technologies0.1043 of 5 stars$0.77flatN/AN/A$3.71M$5.03M0.0050CPHIChina PharmaN/A$0.19flatN/A-59.6%$3.69M$7.78M0.00231GRTSGritstone bio1.1496 of 5 starsN/A$2.17+∞N/A$3.50M$496,000.00-0.03190News CoverageGap DownHigh Trading VolumeOGENOragenicsN/A$0.29+3.6%N/AN/A$3.49M$40,000.00-0.045Analyst ForecastNBYNovaBay Pharmaceuticals0.9332 of 5 stars$0.71+1.4%$0.85+19.2%-93.7%$3.43M$13.84M-0.0130NCNANuCana3.1692 of 5 stars$1.29-3.0%$25.00+1,838.0%-88.1%$3.41MN/A-0.1130TCRTAlaunos TherapeuticsN/A$2.16+2.4%N/A-81.3%$3.38MN/A0.0040 Related Companies and Tools Related Companies CHRO Competitors THAR Competitors ARTL Competitors GENE Competitors CPHI Competitors GRTS Competitors OGEN Competitors NBY Competitors NCNA Competitors TCRT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QLGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QLGN Stock Alerts